Technology
Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179’s Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification
Published
2 months agoon
By

Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher HBsAg loss at EOT48-week EOT data from Cohort 1-3 of the ENSURE study clearly suggests the added benefits of elebsiran towards achieving a higher rate of HBsAg loss in combination with PEG-IFNα
DURHAM, N.C. and BEIJING, China, March 30, 2025 /PRNewswire/ — Brii Biosciences Limited (“Brii Bio,” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, announced new data from its ongoing Phase 2 ENSURE study as a late-breaking oral presentation at the 34th Annual Meeting of Asian Pacific Association for the Study of the Liver (APASL 2025) in Beijing, China.
ENSURE (NCT05970289) is a multicenter, open-label Phase 2 study. Cohorts 1-3 were designed to evaluate the contribution of elebsiran, an investigational small interfering ribonucleic acid (siRNA), in combination with pegylated interferon alpha (PEG-IFNα) in participants with chronic HBV infection with baseline hepatitis B surface antigen (HBsAg) of 100-3,000 IU/mL. Participants who completed 9 doses of BRII-179, a recombinant protein-based therapeutic vaccine, in combination with elebsiran (BRII-835) in a previous APAC study BRII-179-835-001 (NCT04749368) were enrolled to Cohort 4 of this study and received elebsiran and PEG-IFNα combination treatment. The design of Cohort 4 as part of this study was based on insight from previous studies that a significant proportion of the chronic HBV patients fail to generate a sufficient immune response after receiving multiple doses of BRII-179, and therefore unlikely to have the immune support to achieve sustainable functional cure.
Emerging data from Cohort 4 showed that participants who previously had BRII-179 induced anti-HBs response achieved a substantially higher rate of HBsAg seroclearance than those who did not. At Week 24, more than half of the BRII-179 responders (55.6% [10/18]) achieved HBsAg seroclearance, compared to only 10.0% (1/10) in non-responders. These latest data suggest that BRII-179 can serve as a predictive tool for enriching patients more likely to respond to curative therapies.
Additional data from Cohorts 1-3 of the ENSURE study showed that higher end of treatment (EOT) HBsAg loss and seroconversion rates in participants receiving elebsiran in combination with PEG-IFNα than those receiving PEG-IFNα alone.
“The positive Cohort 4 data from the ENSURE study opens new doors for HBV functional cure,” said Dr. Grace Lai-Hung Wong, Professor of Gastroenterology and Hepatology at CUHK Medical Data Analytics Centre (MDAC) and Department of Medicine and Therapeutics in Hong Kong SAR, China. “Previous studies have suggested that BRII-179 may offer a unique opportunity to identify CHB patients who are able to elicit the necessary HBsAg antibody response. I believe these new findings provide clear evidence supporting such value proposition and further substantiate the role of BRII-179 in shaping future combination therapies.”
“We are encouraged that the Cohort 4 from the ENSURE study continue to support our enrichment strategy in developing a functional cure for chronic HBV in target populations,” said David Margolis, MD, Chief Medical Officer of Brii Bio. “The results underscore the potential of BRII-179 in identifying patients who are more likely to respond to regimens aimed at functional cure, thereby enhancing functional cure rates in the target population while reducing exposure to costly therapies for those with a lower probability of cure. We are committed to advancing BRII-179 in combination with various modalities through our ongoing studies and collaborations with strategic partners, aiming to deliver higher functional cure rates to 254 million patients worldwide living with chronic HBV infection.”
Abstract Number: OP0335
Presentation Title: Responders to Prior BRII-179 Treatment Achieved Faster and Higher Rate of HBsAg Seroclearance Following Treatment of Elebsiran and PEG-IFNα in Participants with Chronic Hepatitis B Virus Infection: Preliminary Data from ENSURE Study
Presenter: Grace Lai-Hung Wong, MBChB (CUHK), MD (CUHK), FRCP (Lond, Edin), FHKCP, FHKAM (Medicine), Professor of Gastroenterology and Hepatology at CUHK Medical Data Analytics Centre (MDAC) and Department of Medicine and Therapeutics in Hong Kong SAR, China
Among the 28 of the 31 participants enrolled in Cohort 4 with baseline HBsAg ≥ 100 IU/mL being analyzed, 18 participants with peak anti-HBs ≥ 10 IU/L induced by prior BRII-179 treatment were defined as BRII-179 responders and 10 participants with peak anti-HBs < 10 IU/L were defined as non-responders.At Week 24 of treatment with elebsiran + PEG-IFNα, 39.3% (11/28) of the Cohort 4 participants achieved HBsAg seroclearance.The rate of HBsAg seroclearance at Week 24 in the BRII-179 responders was 55.6% (10/18), notably higher compared to the non-responders at 10% (1/10).Responders to prior BRII-179 treatment appeared to achieve a faster HBsAg seroclearance compared to BRII-179 naïve participants receiving elebsiran + PEG-IFNα as previously reported.Elebsiran and PEG-IFNα combination therapy was generally safe and well tolerated in participants with virally suppressed chronic HBV infection.Treatment with elebsiran + PEG-IFNα is ongoing for 48 weeks.
Abstract Number: LB0009
Presentation Title: Higher end of treatment (EOT) HBsAg loss and seroconversion rates in participants with chronic HBV infection receiving elebsiran (BRII-835) and pegylated interferon alfa-2a (PEG-IFNα) compared to PEG-IFNα alone: Week 48 results from ongoing ENSURE study
Presenter: Jidong Jia, M.D., Ph.D., Professor of Medicine at the Liver Research Centre, Beijing Friendship Hospital, Capital Medical University in Beijing, China
The rates of HBsAg seroclearance at EOT in elebsiran 200 mg + PEG-IFNα and elebsiran 100 mg + PEG-IFNα cohorts were 26.3% (5/19) and 33.3% (6/18), respectively, notably higher compared to PEG-IFNα alone cohort (5.6%) in participants with baseline HBsAg levels 100-3,000 IU/mL.Greater HBsAg reductions at EOT were observed in elebsiran + PEG-IFNα combination cohorts (mean [SE]: -2.47 [0.28] or -3.01 [0.28] log10 IU/mL in elebsiran 200 mg or 100 mg, respectively) than in PEG-IFNα cohort (-1.02 [0.30] log10 IU/mL).Elebsiran in combination with PEG-IFNα at both 200 mg and 100 mg doses achieved similar HBsAg reductions and seroclearance rates. Elebsiran and PEG-IFNα combination therapy was generally safe and well tolerated in participants with virally suppressed chronic HBV infection.Post-treatment follow-up is ongoing and will continue for 24 weeks after discontinuation of treatment.
As part of Brii Bio’s unique approach to developing a functional cure for HBV, the Company and its partners are actively progressing multiple combination studies with our differentiated portfolio, including BRII-179, a recombinant protein-based HBV immunotherapeutic being evaluated in multiple combination studies with elebsiran led by Brii Bio; elebsiran being evaluated in combination with PEG-IFNα in studies led by Brii Bio and tobevibart, an investigational broadly neutralizing monoclonal antibody targeting HBV, being evaluated in multiple Phase 2 and 3 tobevibart and elebsiran combination studies led by Vir Biotechnology. Key data readouts will be shared in the coming months at the scientific conferences throughout 2025.
About Hepatitis B
Hepatitis B virus (HBV) infection is one of the world’s most significant infectious disease threats with more than 254 million people infected globally.[1] Chronic HBV infection is the leading cause of liver disease and an estimated 820,000 people die of complications from chronic HBV infection each year.[1] HBV is of exceptional concern in China, where 87 million people are chronically infected.[2]
About BRII-179
BRII-179 is a novel recombinant protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2, and S HBV surface antigens, and is designed to induce enhanced and broad B-cell and T-cell immunity. In November 2023, the Center for Drug Evaluation (the “CDE”) of the National Medical Products Administration (the “NMPA”) granted BRII-179 Breakthrough Therapy Designation.
About Elebsiran (BRII-835, VIR-2218)
Elebsiran is an investigational subcutaneously administered HBV-targeting siRNA designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. It has the potential to have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. Brii Bio licensed exclusive rights to develop and commercialize elebsiran for the Greater China territory from Vir Biotechnology, Inc. in 2020.
About Brii Bio
Brii Biosciences Limited (“Brii Bio“, stock code: 2137.HK) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit www.briibio.com.
[1] World Health Organization. (April 2024). Global hepatitis report 2024: action for access in low- and middle-income countries. World Health Organization. Retrieved from https://www.who.int/publications/i/item/9789240091672
[2] World Health Organization. Hepatitis. World Health Organization. Retrieved from https://www.who.int/china/health-topics/hepatitis#:~:text=There%20are%2087%20million%20people,living%20with%20chronic%20hepatitis%20C.
View original content to download multimedia:https://www.prnewswire.com/news-releases/brii-bio-unveils-new-data-from-its-ongoing-phase-2-ensure-study-at-apasl-2025-showcasing-brii-179s-unique-potential-to-prime-and-boost-higher-hbsag-loss-through-target-patient-identification-302415033.html
SOURCE Brii Biosciences Limited
You may like
Technology
Manulife Investment Management Announces May 2025 Cash Distributions for Manulife Exchange Traded Funds and ETF Series of Manulife Funds
Published
27 minutes agoon
May 23, 2025By
TSX/NYSE/PSE: MFC SEHK: 945
TORONTO, May 23, 2025 /CNW/ – Manulife Investment Management today announced the May 2025 cash distributions for Manulife Exchange Traded Funds (ETFs) and ETF series of Manulife Mutual Funds, including of Manulife Alternative Mutual Funds (Manulife Funds), that distribute monthly. Unitholders of record at the close of business on May 30, 2025 will receive cash distributions payable on June 13, 2025.
Details of the distribution per unit amounts are as follows:
Manulife ETF/Fund Name
Ticker
Distribution
Amount
(per unit) ($)
Distribution
Frequency
Manulife Smart Short-Term Bond ETF
TERM
0.028063
Monthly
Manulife Smart Core Bond ETF
BSKT
0.021224
Monthly
Manulife Smart Corporate Bond ETF
CBND
0.030917
Monthly
Manulife Smart Global Bond ETF
GBND
0.029073
Monthly
Manulife Smart Enhanced Yield ETF
CYLD
0.160000
Monthly
Manulife Smart U.S. Enhanced Yield ETF – Unhedged
UYLD.B
0.160000
Monthly
Manulife Smart U.S. Enhanced Yield ETF – US Dollar
UYLD.U
0.160000*
Monthly
Manulife Smart U.S. Enhanced Yield ETF – Hedged
UYLD
0.160000
Monthly
Manulife Strategic Income Fund – ETF Series
STRT
0.032774
Monthly
Manulife Alternative Opportunities Fund – ETF Series
OPPS
0.035269
Monthly
Manulife Strategic Income Plus Fund – ETF Series
PLUS
0.043482
Monthly
*Distribution amount ($) in USD.
Commissions, management fees, brokerage fees and expenses all may be associated with exchange traded funds (ETFs) and ETF series. Please read the ETF Facts and prospectus before investing. ETFs and ETF series are not guaranteed, their values change frequently, and past performance may not be repeated. Manulife ETFs and ETF series of Manulife Funds are managed by Manulife Investment Management. Manulife Investment Management is a trade name of Manulife Investment Management Limited.
Manulife Alternative Mutual Funds have the ability to invest in asset classes or use investment strategies that are not permitted for conventional mutual funds. The specific strategies that differentiate these alternative mutual funds from conventional mutual funds may include the increased use of derivatives for hedging and non-hedging purposes, the increased ability to sell securities short and the ability to borrow cash to use for investment purposes. If undertaken, these strategies will be used in accordance with the funds’ objectives and strategies, and during certain market conditions, may accelerate the pace at which the funds decrease in value.
About Manulife Wealth & Asset Management
As part of Manulife Financial Corporation, Manulife Wealth & Asset Management provides global investment, financial advice, and retirement plan services to 19 million individuals, institutions, and retirement plan members worldwide. Our mission is to make decisions easier and lives better by empowering people today to invest for a better tomorrow. As a committed partner to our clients and as a responsible steward of investor capital, we offer a heritage of risk management, deep expertise across public and private markets, and comprehensive retirement plan services. We seek to provide better investment and impact outcomes and to help people confidently save and invest for a more secure financial future. Not all offerings are available in all jurisdictions. For additional information, please visit manulifeim.com.
About Manulife
Manulife Financial Corporation is a leading international financial services provider, helping our customers make their decisions easier and lives better. With our global headquarters in Toronto, Canada, we operate as Manulife across Canada, Asia, and Europe, and primarily as John Hancock in the United States, providing financial advice and insurance for individuals, groups and businesses. Through Manulife Wealth & Asset Management, we offer global investment, financial advice, and retirement plan services to individuals, institutions, and retirement plan members worldwide. At the end of 2024, we had more than 37,000 employees, over 109,000 agents, and thousands of distribution partners, serving over 36 million customers. We trade as ‘MFC’ on the Toronto, New York, and the Philippine stock exchanges, and under ‘945’ in Hong Kong. Not all offerings are available in all jurisdictions. For additional information, please visit manulife.com.
Media contact
Melissa Berczuk
mberczuk@manulife.com
SOURCE Manulife Investment Management
Technology
Bulletin from the annual general meeting in Truecaller AB on 23 May 2025
Published
27 minutes agoon
May 23, 2025By

STOCKHOLM, May 23, 2025 /PRNewswire/ — Today, on 23 May 2025, the annual general meeting was held in Truecaller AB. A summary of the adopted resolutions follows below.
Resolution on adoption of accounts and distribution of the company’s result
The annual general meeting resolved to adopt the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet. The annual general meeting also resolved to allocate the company’s result in accordance with the proposal from the board of directors, meaning that a dividend of SEK 1.70 shall be paid per series A share and series B share, and that the remaining available funds shall be carried forward. It was further resolved that the record date for the dividend shall be 27 May 2025.
Discharge from liability for the board members and the chief executive officer
The annual general meeting resolved to discharge the board members and the chief executive officer from liability for the financial year 2024.
Election and remuneration of the board of directors and auditors
The annual general meeting resolved in accordance with the proposal from the Nomination Committee to re-elect Alan Mamedi, Annika Poutiainen, Helena Svancar, Nami Zarringhalam and Shailesh Lakhani as board members, and to elect Aruna Sundararajan as new board member. Nami Zarringhalam was re-elected as chairman of the board of directors.
Furthermore, the annual general meeting resolved that remuneration to the board shall be paid with SEK 650,000 to the chairman of the board of directors and with SEK 500,000 to each of the other board members. The annual general meeting further resolved that remuneration for committee work shall be paid with SEK 250,000 to the chairman of the Audit Committee, with SEK 100,000 to each of the other members of the Audit Committee, with SEK 150,000 to the chairman of the Remuneration Committee and with SEK 80,000 to each of the other members of the Remuneration Committee.
Finally, the annual general meeting resolved to re-elect Ernst & Young AB as auditor and that the auditor shall be paid in accordance with customary norms and approved invoice. Ernst & Young AB has informed that the authorized public accountant Jennifer Rock-Baley will continue to be the auditor in charge.
Resolution on approval of remuneration report
The annual general meeting resolved to approve the board of directors’ remuneration report for the financial year 2024.
Resolution on guidelines for remuneration to senior executives
The annual general meeting resolved in accordance with the proposal from the board of directors to adopt new guidelines for remuneration to the company’s senior executives.
Resolution on establishment of principles for the Nomination Committee
The annual general meeting resolved in accordance with the proposal from the Nomination Committee on the establishment of principles for the Nomination Committee. The Nomination Committee shall consist of representatives for the three largest shareholders or groups of shareholders in terms of votes as of 30 September 2025.
Resolution on authorization for the board of directors regarding issues
The annual general meeting resolved in accordance with the proposal from the board of directors to authorize the board of directors, at one or several occasions, during the time up until the next annual general meeting, with or without deviation from the shareholders’ preferential rights, and with or without provisions regarding payment in kind or through set-off or other provisions, to resolve to issue new series B shares, convertibles and/or warrants entitling to conversion or subscription of series B shares. The total number of series B shares that may be issued (alternatively be issued through conversion of convertibles and/or exercise of warrants) shall not exceed 38,792,638, which corresponds to a dilution of approximately ten (10) per cent calculated on the number of shares issued at the time of the annual general meeting. To the extent an issue is made with deviation from the shareholders’ preferential rights, the subscription price shall be on market terms (subject to customary new issue discount, as applicable). The purpose of the authorization is to be able to carry out and finance acquisitions of companies and assets and to give the board of directors increased room for maneuver and the opportunity to adapt and improve the company’s capital structure.
Resolution on authorization for the board of directors regarding repurchase and transfer of series B shares in the company
The annual general meeting resolved in accordance with the proposal from the board of directors to authorize the board of directors, at one or several occasions, during the time up until the next annual general meeting, to resolve on repurchase and transfer of series B shares in the company. Repurchase of series B shares may be made of a maximum number of shares so that the company’s shareholding does not, at each time, exceed ten (10) percent of all outstanding shares in the company. Repurchase of series B shares on Nasdaq Stockholm may be made at a price per share within the registered price interval of the company’s series B share at any time, or if the board of directors instructs a member of Nasdaq Stockholm to accumulate a specific number of the company’s shares for its own account during a limited period, at a price per share within the price interval at the time or an equivalent volume-weighted average price. Payment of the series B shares shall be made in cash.
Transfer of series B shares may be made of the total number of shares held by the company from time to time. Transfer may be made with deviation from the shareholders’ preferential rights on Nasdaq Stockholm. Transfer may also be made to third parties in connection with acquisition of companies, operations, or assets. Transfer of series B shares on Nasdaq Stockholm may only be made at a price per share within the registered price interval of the company’s share at the time and if the transfer is made in another way, at a price corresponding to prices in money or value of property received that corresponds to the price of the company’s series B share at the time of the transfer of the shares being transferred with the deviation considered appropriate by the board of directors. Transfer in connection with acquisitions may be made at a market value assessed by the board of directors. Payment for transferred series B shares can be made in cash, through an issue in kind or set-off.
The purpose of the authorizations is to give the board of directors the opportunity to continuously adapt the company’s capital structure and thereby contribute to increased shareholder value, to be able to exploit attractive acquisition opportunities by fully or partly financing future acquisitions of companies, operations, or assets with the company’s own shares, and for financing and/or securing the delivery of series B shares in long-term incentive programs approved by the general meeting.
Resolution on (A) reduction of the share capital by way of cancellation of own shares, and (B) increase of the share capital by way of bonus issue
The board of directors resolved, at the annual general meeting, to withdraw its proposal for (A) cancellation of the company’s own shares and (B) increase of the share capital through a bonus issue, due to the fact that the board of directors was informed prior to the annual general meeting that the hedging measures involving the issue and transfer of own shares in connection with the proposed share programmes will not achieve the required majority. The board of directors therefore considers that a larger holding of own series B shares is appropriate in order to increase the freedom of action in relation to the financing of the delivery of shares to the participants under the programmes.
Resolution on the implementation of a long-term share program 2025:1 and hedging arrangements in respect of the program
The annual general meeting resolved in accordance with the proposal from the board of directors on the implementation of a long-term share program 2025:1 as well as hedging arrangements in accordance with the below.
The share program shall comprise not more than 4,500,000 series B shares and include senior executives, key employees, and certain other employees in the Truecaller group.
In the share program, the participants are allocated a certain number of rights that entitle them to series B shares in the company after the end of a vesting period of two, three and four years, respectively. Following the vesting period, the participants will, free of charge, be allocated shares in the company. Allocation of shares presupposes, with certain limited exceptions, the participant to remain employed within the Truecaller group during the vesting period. In addition, a pre-requisite for the allocation of shares is that certain performance targets are fulfilled by Truecaller regarding revenue growth rate and adjusted EBITDA.
Upon maximum allotment of performance shares a maximum of 4,500,000 series B shares can be issued, corresponding to approximately 1.3 percent of the total number of issued shares and approximately 0.6 percent of the total number of votes in the company
In order to secure delivery of shares to the participants in the share program, the annual general meeting further resolved on hedging measures by way of entering into an equity swap agreement with a third party on terms in accordance with market conditions, whereby the third party in its own name shall be entitled to acquire and transfer series B shares in the company to the participants of the share program.
Resolution on the implementation of a long-term share program 2025:2 and hedging arrangements in respect of the program
The annual general meeting resolved in accordance with the proposal from the board of directors on the implementation of a long-term share program 2025:2 as well as hedging arrangements in accordance with the below.
The share program shall comprise not more than 1,000,000 series B shares for the company’s newly appointed CEO, Rishit Jhunjhunwala.
In the share program, the participant is allocated a certain number of rights that entitle the participant to series B shares in the company after the end of a vesting period of at least approximately three years. Following the vesting period, the participant will, free of charge, be allocated shares in the company. Allocation of shares presupposes, with certain limited exceptions, the participant to remain as the CEO of Truecaller during the vesting period. In addition, a pre-requisite for the allocation of shares is that certain performance targets are fulfilled by Truecaller regarding revenue growth rate and adjusted EBITDA.
Upon maximum allotment of performance shares a maximum of 1,000,000 series B shares can be issued, corresponding to approximately 0.3 percent of the total number of issued shares and approximately 0.1 percent of the total number of votes in the company.
In order to secure delivery of shares to the participant in the share program, the annual general meeting further resolved on hedging measures by way of entering into an equity swap agreement with a third party on terms in accordance with market conditions, whereby the third party in its own name shall be entitled to acquire and transfer series B shares in the company to the participant of the share program.
Stockholm on 23 May 2025
Truecaller AB (publ)
For more information, please contact:
Andreas Frid, Head of IR & Communication
+46 705 290800
andreas.frid@truecaller.com
This information was submitted for publication, through the agency of the contact person set out above, at the time stated by the Company’s news distributor, Cision, at the publication of this press release.
About Truecaller:
Truecaller (TRUE B) is the leading global platform for verifying contacts and blocking unwanted communication. We enable safe and relevant conversations between people and make it efficient for businesses to connect with consumers. Fraud and unwanted communication are endemic to digital economies. especially in emerging markets. We are on a mission to build trust in communication. Truecaller is an essential part of everyday communication for more than 450 million active users. Truecaller is listed on Nasdaq Stockholm since 8 October 2021. For more information. please visit corporate.truecaller.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/20429/4154818/3467808.pdf
Truecaller – Bulletin from Annual General Meeting 2025
View original content:https://www.prnewswire.com/news-releases/bulletin-from-the-annual-general-meeting-in-truecaller-ab-on-23-may-2025-302464218.html
SOURCE Truecaller AB
Technology
Enterprises from 39 Countries Join WCIFIT, with Thailand, Hong Kong, and Sichuan in the Spotlight
Published
27 minutes agoon
May 23, 2025By

CHONGQING, China, May 23, 2025 /PRNewswire/ — A news report from iChongqing: Over 1,300 enterprises from 39 countries and regions gathered in Chongqing on May 22 for the 7th Western China International Fair for Investment and Trade (WCIFIT), highlighting rising global interest in the region’s economic potential. The event drew participants from 28 Chinese provinces and the Hong Kong Special Administrative Region, showcasing the latest in trade and innovation.
The fair also featured the debut of Lingjie, the world’s first megawatt-class supercharging heavy-duty truck, co-developed by Qingling Motors and Huawei Digital Power. With ultra-fast charging and smart connectivity, it marks a major step forward in green logistics and heavy-duty transport electrification.
Centered around the theme “New Western China, New Manufacturing, New Services,” this year’s fair highlights cultivating new quality productive forces and promoting high-quality development.
56 Chinese central state-owned enterprises, 156 local state-owned enterprises, 47 Fortune Global 500 companies, 93 multinational corporations, and 286 leading private enterprises participated.
Thailand is participating as the guest country of honor, Sichuan Province continues its role as the permanent guest province, and the Hong Kong Special Administrative Region joins as the new guest city of honor.
Dr. Lalivan Karnchanachari, Vice Minister to Ministry of Foreign Affairs of Thailand, highlighted the significance of this year marking the 50th anniversary of diplomatic ties between China and Thailand. She expressed hopes for deeper cooperation with Chongqing in high value-added manufacturing, supply chains, and SME development.
At the opening ceremony, a series of major investment deals were signed, with the total amount exceeding 200 billion yuan (about 27.6 billion USD). Districts and counties across Chongqing secured agreements worth over 100 billion yuan, with more than 75% of the investment directed toward the manufacturing and modern services sectors.
Showcasing both exhibitions and themed activities, this year’s WCIFIT exhibition spans three major sections—comprehensive image, international and regional cooperation, and modern industry—covering nine halls across 110,000 square meters. A virtual exhibition hall has also been launched to extend access online.
Themed activities include 29 events focused on key areas such as the productive service industry, foreign investment, international trade, public sector engagement, and special programs hosted by the guest of honor.
View original content to download multimedia:https://www.prnewswire.com/news-releases/enterprises-from-39-countries-join-wcifit-with-thailand-hong-kong-and-sichuan-in-the-spotlight-302464219.html
SOURCE iChongqing

Manulife Investment Management Announces May 2025 Cash Distributions for Manulife Exchange Traded Funds and ETF Series of Manulife Funds

Bulletin from the annual general meeting in Truecaller AB on 23 May 2025

Enterprises from 39 Countries Join WCIFIT, with Thailand, Hong Kong, and Sichuan in the Spotlight

Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network

New Gooseneck Omni Antennas Offer Enhanced Signals in a Durable Package

Huawei Launches Global City Intelligent Twins Architecture to Accelerate City Digital Transformation

Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs

Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network

NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Near Videos5 days ago
HOT Protocol: Web3 Access for 30 Million Users
-
Coin Market2 days ago
Hong Kong passes stablecoin bill, set to open licensing by year-end
-
Technology3 days ago
XREAL Unveils ‘Project Aura’ at Google I/O — An Optical See-Through XR Device for Android XR
-
Technology1 day ago
RD Technologies Celebrates Passage of Stablecoins Ordinance in Hong Kong
-
Near Videos4 days ago
Hot Protocol is Redefining Crypto Wallets and HOT Wallet Mobile + Extension Launch
-
Technology4 days ago
HYTE’s Nexus Software Continues Innovative Developments With Nexus 2. 3 And New Accessories Revealed At Computex
-
Coin Market5 days ago
Pavel Durov rejects EU pressure to censor Romanian election content
-
Technology4 days ago
Agoda Spotlights Lantern Festivals Across Asia to Brighten the Year